Literature DB >> 26394134

Sacral Neuromodulation for Genitourinary Problems.

Mai Banakhar, Magdy Hassouna.   

Abstract

Sacral neuromodulation (SNM) is a minimally invasive therapeutic option for many voiding dysfunction conditions. It is approved by the US FDA for refractory overactive bladder with and without incontinence and nonobstructive retention. Since SNM has shown a favorable response for these approved indications, other therapeutic applications have been proposed for various conditions such as painful bladder syndrome, chronic pelvic pain and neurological voiding dysfunction in both adult and pediatric age groups. SNM therapy with the most commonly used dedicated SNM device (InterStim) involves insertion of electrode(s) in the third and/or fourth sacral foramen next to the nerve root. The electrode is then connected to a battery-operated pulse generator. All patients need to have a test trial period before definitive device insertion. Here we discuss SNM therapy in functional urinary disorders and the technique of device insertion with the potential pitfalls.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2015        PMID: 26394134     DOI: 10.1159/000434671

Source DB:  PubMed          Journal:  Prog Neurol Surg        ISSN: 0079-6492


  3 in total

Review 1.  [Sacral neuromodulation in under- and overactive detrusor-quo vadis? : Principles and developments].

Authors:  F Girtner; M Burger; R Mayr
Journal:  Urologe A       Date:  2019-06       Impact factor: 0.639

Review 2.  Neuropelveology: An Emerging Discipline for the Management of Chronic Pelvic Pain.

Authors:  Marc Possover; Karl-Erik Andersson; Axel Forman
Journal:  Int Neurourol J       Date:  2017-12-31       Impact factor: 2.835

3.  Protocol for a randomized clinical trial investigating early sacral nerve stimulation as an adjunct to standard neurogenic bladder management following acute spinal cord injury.

Authors:  Jeffrey D Redshaw; Sara M Lenherr; Sean P Elliott; John T Stoffel; Jeffrey P Rosenbluth; Angela P Presson; Jeremy B Myers
Journal:  BMC Urol       Date:  2018-08-29       Impact factor: 2.264

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.